HER2 Low-Positive Breast Cancer: A Potential New Subtype for Precision Treatment
Author: Cornflower This article is published with the author’s permission by Yiliao Tong. Please do not reproduce without authorization. Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a highly aggressive molecular subtype with poor prognosis. The advent of anti-HER2 targeted therapies has significantly improved its prognosis. Currently, international standards generally consider that … Read more